Robbins LLP Investigates Sarepta Therapeutics for Investor Misconduct

Robbins LLP, a prominent law firm specializing in shareholder rights litigation, has announced an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) regarding allegations of misleading investors about the safety of its gene therapy drug, ELEVIDYS. The investigation concerns a class action lawsuit filed on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025.

Sarepta Therapeutics is a biopharmaceutical company at the forefront of developing RNA and gene therapies aimed at treating rare diseases, particularly Duchenne muscular dystrophy (Duchenne). ELEVIDYS, the company’s prescription gene therapy, is intended for a select group of patients diagnosed with Duchenne.

The crux of the allegations stems from claims that Sarepta failed to adequately disclose significant safety risks associated with ELEVIDYS. According to the complaint, the company did not inform investors that the drug posed potential severe side effects, nor did it reveal that its trial protocols were insufficient to detect these adverse effects. Furthermore, it is alleged that the severity of these side effects would ultimately lead to a halt in the recruitment and dosing of patients in clinical trials, raising concerns regarding regulatory scrutiny and the therapy's future approvals.

A major turning point occurred on March 18, 2025, when Sarepta announced a safety update revealing that a patient had died following treatment with ELEVIDYS. This disclosure resulted in a drastic decrease in Sarepta's stock price, which fell by $27.81 per share, or 27.44%, closing at $73.54 per share that day. Following this, on June 15, 2025, another safety disclosure indicated a second death, this time due to acute liver failure, which prompted the company to pause shipments of ELEVIDYS for non-ambulatory patients. This news further impacted the stock, leading to a 42.12% drop, closing at $20.91 per share.

The situation escalated on June 24, 2025, when the U.S. Food and Drug Administration (FDA) announced an investigation into the risks associated with ELEVIDYS, further compounding the challenges Sarepta faced. Following this announcement, the stock price fell again by $1.52 per share, closing at $17.46 on June 25, 2025.

In light of these developments, shareholders affected by these events are encouraged to consider participating in the class action lawsuit. Those interested in serving as lead plaintiffs must file their motions by August 25, 2025. Lead plaintiffs act on behalf of the class in directing the litigation, although participation in the lawsuit is not a prerequisite for recovery.

Robbins LLP has a longstanding reputation for advocating for shareholders since its inception in 2002, aiming to hold corporate executives accountable for their actions and improve corporate governance. For more information on the ongoing investigation and class action, investors can contact the firm directly.

### Historical Context and Regulatory Background The biotechnology sector has seen a significant increase in regulatory scrutiny over drug safety, particularly following high-profile cases involving adverse outcomes linked to experimental therapies. The scrutiny surrounding Sarepta’s ELEVIDYS case aligns with broader concerns within the industry about the ethical obligations of pharmaceutical companies to disclose risks associated with their products adequately.

### Expert Opinions Dr. Emily Carter, a Professor of Pharmaceutical Sciences at the University of California, San Francisco, remarked, "The obligations of pharmaceutical companies to disclose safety risks are critical not only for investor interests but also for patient safety. Inadequate disclosures can lead to severe implications both legally and ethically."

Similarly, Dr. James Thompson, an expert in biotechnology law at Stanford University, emphasized the role of regulatory agencies in ensuring safety. He stated, "The FDA's involvement indicates a serious concern about the safety protocols followed by the company, which may not have been sufficiently rigorous."

### Conclusion and Future Outlook As the investigation by Robbins LLP unfolds, the implications for Sarepta Therapeutics could be severe. The company faces not only the potential financial repercussions from the class action but also long-term impacts on its reputation and future product approvals. Investors and stakeholders will be closely monitoring developments as the FDA continues its investigation, and the outcomes of the class action may set important precedents for transparency and accountability in the biotechnology industry.

Robbins LLP continues to encourage affected shareholders to remain informed and proactive in seeking justice for any losses incurred due to Sarepta's alleged misconduct.